Ocugen’s Dual-Continent Roadshow Kicks Off as FDA Filing Window Nears

Ocugen races to secure funding and regulatory approvals for three BLA targets by 2028, with lead candidate OCU400 Phase 3 data expected in early 2027.

The biotech’s top brass is splitting up this week to cover more ground. While chief executive Shankar Musunuri pitches to investors in Puerto Rico, his colleague Abhi Gupta is working the room in Rome. The synchronized charm offensive comes at a pivotal moment for Ocugen, which is racing to secure both regulatory approvals and the funding needed to get there.

Shareholders will have their say on June 11, when the company holds a virtual annual meeting. The agenda covers the usual housekeeping: electing two board members, approving executive compensation, and deciding how often future pay votes should occur. The proxy statement, filed with the SEC, doubles as a detailed progress report on the pipeline.

Three BLA Targets by 2028

Ocugen is aiming to submit up to three biologics license applications by 2028. The lead candidate, OCU400 for retinitis pigmentosa, has already completed enrollment in its pivotal Phase 3 trial. A rolling BLA submission is slated for the third quarter of 2026, with key data expected in the first quarter of 2027 to support final approval. In Europe, the EMA has granted permission for a centralized marketing application, which should streamline the process.

The Stargardt disease program, OCU410ST, is also moving quickly. Dosing wrapped up in under nine months. Management anticipates initial results in spring 2027, with a formal BLA filing targeted for mid-2027. A third candidate, OCU410, is set to begin a Phase 3 trial in late summer.

Cash Runway Stretches—But Only Just

Funding these ambitions won’t come cheap. A January capital raise brought in roughly $22.5 million, and together with exercised warrants, the company expects its liquidity to last into the fourth quarter of 2026. That’s a tight window for a firm that generated just $4.4 million in revenue last year. In March, auditors flagged substantial doubt about Ocugen’s ability to continue as a going concern.

The stock is reflecting that tension. Shares trade around €1.44, having gained more than 130% over the past twelve months. But the ride has been volatile: the stock shed nearly 8% in the past week alone. The next financial report, due in May, will force management to spell out how it plans to finance the expensive late-stage trials.

The real test comes in the third quarter, when Ocugen files its rolling BLA for OCU400. A positive FDA decision could ease the auditor’s concerns and buy the company the breathing room it needs. Until then, the roadshow continues.